Usually not. Of the 71 sellers publishing both a semaglutide injection and a semaglutide tablet, 37 charge more for the tablet. The median difference is $9 a month, in the tablet’s direction.
Most readers arrive expecting the opposite. No needle, no cold chain, no sharps. The corpus does not agree, and the reason the belief survives is a measurement problem. Pooled across the whole market the formats look close, at $179 against $227. Only a seller publishing both can price the format itself.
Readers usually arrive expecting a tablet to be cheaper than an injection. No needle, no cold chain, no sharps. On this corpus that is wrong more often than right. The cleanest way to show it is to compare sellers against themselves rather than against each other.
The paired result
71 sellers on this desk publish a figure for both compounded semaglutide by injection and an oral semaglutide. That is a subset of the market mapped in the full price distribution. Of those, 37 price the tablet higher — 52% of the paired set. The median difference is $9 a month in the tablet’s direction.
Tirzepatide shows the same shape on a smaller sample. 36 sellers publish both formats and 15 charge more for the tablet. The median difference is $0.
What the premium is actually buying
A daily tablet instead of a weekly injection. For some people that is the whole decision. For others it is worth nothing. What it is not buying is a lower bill. Nor is it the only premium hiding in a headline, as the gap between advertised and billed shows. Some sellers do price the tablet below the injection. Notice that as the exception rather than assuming it as the rule.
There is a second reason not to read the two figures as interchangeable. Several oral lines on this desk are sublingual formulations, and sublingual milligrams do not read across to injected ones. A tablet priced near an injection is not the same dose at a similar price. It is a different product, and the seller usually does not state its equivalence. That is one more thing most sellers leave unpublished.
Checking a specific pair
The head-to-head pages carry several sellers whose format premium runs the other way. And the six-month totals show what each choice compounds to. Figures are computed from this site’s own price records at build time, most recently read September 2026.
Why the tablet costs more
The manufacturing estimate points the same way as the price desk. A production-cost analysis puts injectable semaglutide at $28 to $140 per person-year and an oral formulation at $186 to $380 [1]. The tablet is the dearer thing to make. A needle looks like the expensive part and is not.
The formats are not far apart on results. An indirect comparison bridged trials of oral semaglutide 25 mg and injectable semaglutide 2.4 mg[2]. Efficacy was comparable on every outcome assessed. The injection held 1.01 percentage points on weight change, with an interval from −1.61 to 3.63. Nobody was randomized between the two, which is why that comparison is bridged rather than head to head.
So the tablet usually costs more, and does about the same. It buys convenience. A third of sellers price it the other way, which is worth checking before assuming either.